Sep. 9, 2009 (Business Wire) -- BioScrip, Inc. (Nasdaq: BIOS) today announced that Richard M. Smith, President and Chief Operating Officer, has been appointed to its Board of Directors. The addition of Mr. Smith increases the number of directors to nine members. Mr. Smith has served as BioScrip’s President and Chief Operating Officer since joining the Company in January of this year.
Richard H. Friedman, Chairman and Chief Executive Officer, said, “Rick is a welcome addition to BioScrip’s Board of Directors. His experience, results-driven focus and customer insight continue to help BioScrip on its strategic course, with the goal of increasing overall shareholder value.”
“I’m delighted to be a part of our Board, especially as we continue to focus on expanding our footprint and establishing BioScrip as the industry leader in the clinical management of chronic patients who require infusion, oral and injectible specialty medications,” said Smith, President and Chief Operating Officer. “We have had solid momentum so far this year and we are well positioned for success now and into the future.”
About BioScrip, Inc.
BioScrip, Inc. (www.bioscrip.com) (Nasdaq: BIOS) is a specialty pharmaceutical healthcare organization that partners with patients, physicians, healthcare payors and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex healthcare conditions.
Forward Looking Statements
This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward looking statements as a result of various factors. Important factors that could cause such differences are described in the Company's periodic filings with the Securities and Exchange Commission.
